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High Concentrations of Measles Neutralizing Antibodies and High-
Avidity Measles IgG Accurately Identify Measles Reinfection Cases
Sun B. Sowers, Jennifer S. Rota, Carole J. Hickman, Sara Mercader, Susan Redd, Rebecca J. McNall, Nobia Williams, Marcia McGrew,
M. Laura Walls, Paul A. Rota, William J. Bellini
National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
In the United States, approximately 9% of the measles cases reported from 2012 to 2014 occurred in vaccinated individuals. Lab-
oratory confirmation of measles in vaccinated individuals is challenging since IgM assays can give inconclusive results. Although
a positive reverse transcription (RT)-PCR assay result from an appropriately timed specimen can provide confirmation, negative
results may not rule out a highly suspicious case. Detection of high-avidity measles IgG in serum samples provides laboratory
evidence of a past immunologic response to measles from natural infection or immunization. High concentrations of measles
neutralizing antibody have been observed by plaque reduction neutralization (PRN) assays among confirmed measles cases with
high-avidity IgG, referred to here as reinfection cases (RICs). In this study, we evaluated the utility of measuring levels of measles
neutralizing antibody to distinguish RICs from noncases by receiver operating characteristic curve analysis. Single and paired
serum samples with high-avidity measles IgG from suspected measles cases submitted to the CDC for routine surveillance were
used for the analysis. The RICs were confirmed by a 4-fold rise in PRN titer or by RT-quantitative PCR (RT-qPCR) assay, while
the noncases were negative by both assays. Discrimination accuracy was high with serum samples collected >3 days after rash
onset (area under the curve, 0.953; 95% confidence interval [CI], 0.854 to 0.993). Measles neutralizing antibody concentrations of
>40,000 mIU/ml identified RICs with 90% sensitivity (95% CI, 74 to 98%) and 100% specificity (95% CI, 82 to 100%). Therefore,
when serological or RT-qPCR results are unavailable or inconclusive, suspected measles cases with high-avidity measles IgG can
be confirmed as RICs by measles neutralizing antibody concentrations of >40,000 mIU/ml.
Despite continued importations of measles virus into theUnited States, the elimination of indigenous measles has
been maintained for over 15 years because of sustained high cov-
erage with two doses of measles-mumps-rubella (MMR) vaccine
(1–3). Many countries have eliminated measles or have made sig-
nificant progress toward achieving goals for measles elimination
(4). However, measles remains endemic in many parts of the
world and both sporadic cases and large outbreaks have occurred
in the United States following importations of the virus (5, 6).
Although most measles cases in the United States have occurred
among unvaccinated individuals, some confirmed cases have oc-
curred among vaccinated and presumptively immune individuals
(7, 8). In populations with high vaccination coverage, the number
of susceptible individuals who are vaccinated will increase with
time and will make up a larger proportion of the measles cases (9).
Laboratory confirmation of measles virus infection is a critical
component of the surveillance required to support measles con-
trol and elimination programs. Though detection of measles vi-
rus-specific IgM by enzyme immunoassay (EIA) is the most
widely used method to confirm measles virus infection, suspected
measles cases in highly vaccinated populations may require addi-
tional testing. Inconclusive results obtained by IgM testing can be
confirmed by detection of measles virus RNA by reverse transcrip-
tion (RT)-PCR.
A suspected measles case in a previously vaccinated individual
can be classified as a primary vaccine failure (PVF) by measure-
ment of low-avidity measles IgG antibody (10). Individuals with
confirmed measles and a prior immunologic response to measles
virus (reinfection) from either vaccination or natural disease that
occurred at least 4 months before symptom onset can be identified
by the presence of high-avidity measles IgG antibody (10–13). A
measles virus reinfection that occurs in an individual who had
measurable specific antibodies after documented vaccination
constitutes a secondary vaccine failure (SVF) (14–16). However,
the vaccination history of some persons with confirmed reinfec-
tions can be unknown, and among those with 1 documented
doses of vaccine, evidence of a protective titer of antibody to
measles following vaccination is rarely available. Therefore, the
term reinfection case (RIC) can be universally applied to a
confirmed measles case in a person with high-avidity measles
IgG antibody.
Serum samples collected at or near the onset of rash from RICs
often have undetectable measles-specific IgM while high levels of
measles-specific IgG are present (16–18). Therefore, the best
method for case confirmation of a RIC is RT-PCR testing. How-
ever, reliable and dependable RT-PCR results depend on high-
quality RNA extracted from specimens that have been adequately
collected and transported to the laboratory in a timely manner.
Because a good-quality specimen cannot be ensured, a negative
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RT-PCR result does not rule out a suspicious case. This may be
especially problematic for RICs since the duration of viral shed-
ding may be diminished and measles may not be initially sus-
pected among those RICs with mild symptoms or unusual rash
presentation and progression (18–21). However, measurement of
high concentrations of measles neutralizing antibodies by the
plaque reduction neutralization (PRN) assay, previously observed
among confirmed measles cases with high-avidity measles IgG,
may provide an alternative method to confirm RICs when stan-
dard laboratory tests are inconclusive (11, 22).
In this study, persons suspected of having measles with high-
avidity measles IgG antibody in serum were tested by standard
laboratory methods and were classified as having either a RIC or a
rash illness not attributable to measles (noncase). Receiver oper-
ating characteristic (ROC) curve analysis was performed by using
measles neutralizing antibody concentrations from these two
groups as the discriminating variable to evaluate the use of neu-
tralizing antibody concentrations to distinguish between RICs
and noncases.
MATERIALS AND METHODS
Study samples and routine diagnostic methods. Clinical samples from
persons with suspected cases of measles included in this study were sub-
mitted to the Centers for Disease Control and Prevention (CDC) for rou-
tine confirmatory testing during 2006 to 2014. As part of routine surveil-
lance, serum samples were tested for measles-specific IgM with the CDC
measles IgM capture EIA and measles-specific IgG was detected with ei-
ther the CDC measles IgG indirect EIA (23) or a commercially available
measles IgG indirect EIA (Wampole Laboratories, Inc. Princeton, NJ,
USA). Specimens for virus detection (throat swab, nasopharyngeal swab,
and urine) were tested with a measles real-time RT-quantitative PCR (RT-
qPCR) assay as previously described (24). In this group, there were 149
persons with suspected cases and positive results for measles-specific IgG
in serum that were evaluated according to the criteria provided for inclu-
sion in the ROC analysis (see below). Most of these samples were submit-
ted from the United States; however, samples were also referred from the
Federated States of Micronesia and the national laboratory in Colombia.
Any case patients known to have received immunoglobulin as postexpo-
sure prophylaxis or noted to have a medical condition that could poten-
tially diminish their immune response were excluded. In addition, pa-
tients who had received a postexposure dose of MMR vaccine were
excluded unless infection with wild-type measles virus was confirmed by
sequencing. Epidemiologic data associated with the suspected cases were
compiled from the CDC specimen submission form or the National No-
tifiable Disease Surveillance System. Additional sources of information
included telephone or email correspondence with epidemiologists or
other public health staff involved in the investigation of the cases. The data
collected included the setting in which the suspected case was identified
(outbreak-associated or sporadic case), any known exposure or risk fac-
tors, known link to a secondary case, and vaccination (MMR vaccine)
status.
Terminology and criteria for inclusion in the ROC analysis. In this
report, RIC is used to define a confirmed case of measles in an individual
with high-avidity measles IgG, and the definition applies whether the
previous immune response was elicited by vaccination or by wild-type
infection. In the absence of a gold standard assay for measles virus rein-
fection, the criteria for inclusion of a suspected measles case as a RIC
required the measurement of high-avidity measles IgG in serum and lab-
oratory confirmation of acute measles by detection of measles virus RNA
by RT-qPCR or measurement of a 4-fold rise in PRN titer between two
paired serum samples (Fig. 1). A suspected measles case with high-avidity
measles IgG in serum could be considered for inclusion as a noncase only
if two serum samples and a companion viral specimen had been collected.
The criteria for inclusion as a noncase required that the viral specimen
tested negative by RT-qPCR and a 4-fold rise in titer between paired
serum samples by PRN was not demonstrated.
Measles IgG avidity determination. Measles IgG avidity was mea-
sured in serum samples with an assay developed at the CDC by using a
commercial measles IgG EIA (Captia Measles IgG; Trinity Biotech, James-
town, NJ, USA) modified for use with the denaturing agent diethylamine
as previously described (10).
FIG 1 Classification scheme of RICs and noncases included in the ROC analysis and derivation of suspected cases evaluated following the ROC analysis.
High-avidity measles IgG antibody in serum was the first criterion for inclusion of RICs and noncases in the ROC analysis. The RICs included in the ROC analysis were
confirmed by either a 4-fold rise in serum PRN titer or a positive RT-qPCR result, while noncases had no 4-fold rise in serum PRN titer and viral specimens were negative
by RT-qPCR. *, measles-specific IgG was detected either by the CDC measles IgG indirect EIA or by a commercially available measles IgG indirect EIA.
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PRN assay. Serum was tested for measles neutralizing antibody by the
PRN assay (25). The World Health Organization (WHO) second interna-
tional standard antimeasles serum (IS, coded 66/202, supplied by the Na-
tional Institute for Biological Standards and Control, South Mimms,
United Kingdom) was included to calculate the reciprocal of the 50%
endpoint titer by the Kärber method. With the validation of the second
WHO standard serum, PRN titers were expressed in mIU/ml. A titer of 1:8
was equivalent to a concentration of 8 mIU/ml.
Statistical analysis. ROC curve analysis was used to estimate the ac-
curacy of the parameter (measles neutralizing antibody concentration) to
distinguish between a RIC and a noncase on the basis of the area under the
ROC curve (AUC). ROC analysis was used to establish a cutoff based on
the measles neutralizing antibody concentration and to estimate sensitiv-
ity and specificity (26). The null hypothesis for sample size calculation was
an AUC of 0.80 (moderate diagnostic accuracy) and standard error of
the AUC of 5% (27). RICs and noncases for the ROC analyses were
defined above. An initial ROC analysis was conducted with the measles
neutralizing antibody concentrations obtained with the first (or only)
serum sample collected after rash onset. A second ROC analysis was per-
formed with measles neutralizing antibody concentrations from those
RIC patients that had a follow-up serum sample collected 3 days after
rash onset. If multiple follow-up serum samples were collected, the mea-
sles neutralizing antibody concentration from the earliest follow-up sam-
ple collected after 3 days was used.
ROC analysis was performed and graphs were prepared with MedCalc
for Windows, version 13.1.1.0 (MedCalc Software, Ostend, Belgium). The
significance of the differences between the groups defined in this study
was determined with the t statistic for comparison of two small sample
means. All tests of significance were two tailed and unpaired. A P value of
0.05 was considered significant. Geometric mean concentrations
(GMCs) were determined by using the measles neutralizing antibody con-
centrations obtained with the PRN assay. Therefore, GMC refers to the
GMC derived from PRN titers expressed in mIU/ml.
The box-and-whisker plots and comparison tests were generated with
GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Outlier
and extreme outlier values were identified on the basis of the standard
parameters for box- and-whisker plots. The values for Q1  1.5  IQR
(interquartile range) and Q3  1.5  IQR are the “inner” fences, and the
values for Q1  3  IQR and Q3  3  IQR are the “outer” fences. The
outliers (shown as solid circles) are between the inner and outer fences,
and the extreme outliers (shown as squares or triangles) are outside the
outer fences.
RESULTS
Measles IgG avidity testing. Of the 149 suspected measles cases
with a serum sample that tested positive for measles IgG and had
sufficient volume remaining for additional testing (Fig. 1), high-
avidity measles IgG antibody was detected in serum samples from
97 cases and low-avidity measles IgG antibody was present in
samples from 27 cases. The remaining 25 suspected cases had
insufficient sample volume to complete avidity testing (n 
22), or the avidity result was in the intermediate range (n  3).
These 25 suspected cases, which could include noncases, pri-
mary cases, and RICs, and the 27 cases with low-avidity measles
IgG antibody measured in serum were excluded from the ROC
analysis (Fig. 1).
Among the 97 suspected cases identified as having serum sam-
ples with high-avidity measles IgG, there were 77 (79%) cases for
which a viral specimen had been tested by RT-qPCR and two
serum samples were available to test for the presence of a 4-fold
rise in PRN titer. Specimens from 20 of the 77 suspected cases were
negative by RT-qPCR and had no 4-fold rise in PRN titer and
therefore met the criteria for noncases.
Fifty-seven persons with suspected cases whose serum samples
contained high-avidity measles IgG were laboratory confirmed as
having acute measles by one or both of the methods required for
inclusion as a RIC (Fig. 1). Forty-eight (84%) of the 57 RICs were
confirmed by detection of measles virus RNA by RT-qPCR (with
or without a concomitant 4-fold rise in PRN titer between paired
serum samples), and the remaining 9 RICs (16%) were confirmed
by determination of a 4-fold rise in PRN titer. Of the 57 RICs, 31
(54%) had an additional serum sample collected 3 days after
rash onset. Among the original 97 suspected cases with high-avid-
ity measles IgG detected in serum, 20 could not be classified as
either a noncase or a RIC according to the study criteria and were
not included in the ROC analysis.
Laboratory and epidemiologic characteristics of RICs and
noncases. The age range of the RICs was 2 to 65 years, and that of
noncases was 1.5 to 61 years (data not shown). The median age of
the RICs was significantly greater (P  0.0001) than that of the
noncases (30 versus 10.5 years). The gender composition of the
RICs was equally divided, with 29 males and 28 females, whereas
there were only 6 (30%) females among the 20 noncases (data not
shown). Among the RICs, the proportion of positive IgM results
increased from 51 to 68% after testing of the second serum
sample, while the number of IgM-positive samples decreased
slightly among the noncases between the first and second sam-
ples (Table 1).
A greater proportion of the RICs than the noncases was asso-
ciated with a higher index of suspicion of measles (known contact
with a person with a confirmed case of measles, investigated as
part of an outbreak, or association with recent travel) (Table 1).
TABLE 1 Characteristics of suspected measles cases included in each ROC analysis with epidemiologic context described for RICs and noncases






















Sample 1 (57) 18 (31) 0–11 (2) 29 (51) 35 (61) 56 (98) 5 (9) 33 (58)
Sample 2 (31) 28 (90) 3–30 (6) 21 (68)
Noncases (20)
Sample 1 (20) 1 (5) 0–11 (2) 9 (45) 2 (10) 5 (25) 0 (0) 17 (85)
Sample 2 (20) 1 (5) 5–42 (9) 8 (40)
a Concentration, in mIU/ml, of measles neutralizing antibody determined by PRN assay.
b Interval, in days after rash onset, of serum collection.
c Positive by CDC measles IgM capture assay.
d Receipt of one or more doses of MMR vaccine according to case investigation.
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Five (8.8%) of the RICs were known to have been the source of
infection of subsequent cases of measles, whereas there were no
suspected sources among the noncases. Of the RIC patients, 58%
had a vaccination history of one or more doses of MMR vaccine,
while the proportion among the noncases was 85%.
ROC analysis. The measles neutralizing antibody concentra-
tions calculated for the serum samples from the RICs and non-
cases were evaluated in two separate ROC analyses (Fig. 2). The
first ROC analysis (ROC1) was conducted with the measles neu-
tralizing antibody concentrations of 77 serum samples, i.e., the
first (or only) serum sample collected from 57 RICs and the first
serum sample collected from the 20 noncases. The second ROC
analysis (ROC2) was performed with measles neutralizing anti-
body concentrations of 51 serum samples that included the fol-
low-up serum samples available from 31 of the 57 RICs and the
second serum sample from the 20 noncases. In ROC1, serum sam-
ples were collected 0 to 11 days after rash onset and the accuracy
with which the RICs were distinguished from the noncases was
moderate (AUC  0.785; 95% CI, 0.677 to 0.871) (Fig. 2). In
ROC2, the accuracy was high (AUC  0.953; 95% CI, 0.854 to
0.993) (Fig. 2) with measles neutralizing antibody concentrations
in those serum samples collected 3 days after rash onset.
Analysis of measles neutralizing antibody concentrations
and identification of outliers among the RICs and noncases. The
GMC of the 57 RICs with serum samples collected between 0 and
11 days after rash onset (ROC1) was 12,281 mIU/ml. This was
significantly different (P  0.0001) from the GMC (85,475 mIU/
ml) of the 31 follow-up samples (ROC2) (Fig. 3). No significant
difference was observed between the GMCs of the noncases in
ROC1 (1,791 mIU/ml) and ROC2 (1,646 mIU/ml).
Two data points were identified as extreme outliers in each
ROC analysis. These two measles neutralizing antibody concen-
trations were from the same noncase (case X). The first serum
sample, collected on day 3, had a concentration of 107,712 mIU/
ml; the second serum sample (day 10) had a concentration of
94,860 mIU/ml (Fig. 3, triangle shapes). Although case X met the
study criteria for a noncase, with no 4-fold rise and a negative
RT-qPCR result, the case X patient had known contact with some-
one with a confirmed case of measles and was reported as having a
confirmed case. However, despite the inclusion of case X as a
noncase, the difference in the GMCs of the RICs and the noncases
was significant (ROC1, P  0.0112; ROC2, P  0.0001).
Selection of the neutralization cutoff for discriminating be-
tween RICs and noncases. Measles neutralizing antibody concen-
trations of 40,000 mIU/ml were obtained from the first serum
sample collected from 18/57 (31%) RICs and from 28/31 (90%)
RICs with a second serum sample collected (Table 1). Thirty-six
(63%) of the 57 serum samples evaluated in ROC1 were collected
on days 0 to 2. These samples had concentrations that ranged from
81 to 236,295 mIU/ml (GMC  5,214 mIU/ml). The concentra-
tions of serum samples from the remaining 21 RICs, collected on
days 3 to 11, ranged from 2,576 to 234,616 mIU/ml (GMC 
53,329 mIU/ml) (data not shown). Combining all of the RICs that
had a first or a follow-up serum sample collected at 3 days after
rash onset (n  49), 41 (83.7%) had measles neutralizing antibody
concentrations of 40,000 mIU/ml.
A cutoff of 40,000 mIU/ml had a specificity of 95% (95% CI, 75
to 100%) for confirmation of RICs. Furthermore, this cutoff ac-
commodates the 3-fold variation inherent in the PRN assay (25).
The specificity increased to 100% (95% CI, 82 to 100%) when two
outlier values from a probably misclassified noncase were ex-
cluded (case X, discussed above) (Fig. 3). With the neutralizing
antibody concentrations from serum samples collected at 3 days
in ROC2, (n  31), the sensitivity of the cutoff to identify RICs was
90% (95% CI, 74 to 98%).
Application of the neutralization cutoff to suspected cases
that were excluded from the ROC analysis. Measles neutralizing
antibody concentrations were available from the two groups that
were excluded from the ROC analysis (see Fig. S1 in the supple-
mental material). Serum samples from 17 of the 20 suspected cases
with high-avidity measles IgG antibody had at least one serum
sample with a concentration of 40,000 mIU/ml and were
FIG 2 ROC curve analyses of concentrations of measles neutralizing antibodies determined by PRN assays of serum specimens from RICs and noncases. The
ROC1 analysis was performed with the first (or single) sample collected. The ROC2 analysis was performed with available second samples collected from the same
cases 3 days after rash onset. The AUC is plotted as a solid line. The diagonal line is an AUC of 0.5, interpreted as a random guess. The 95% CIs are in parentheses
and are plotted as dashed lines.
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designated confirmed RICs (cRICs). Eight of the 25 IgG-posi-
tive suspected cases with inconclusive avidity results (not
tested or intermediate avidity) had at least one serum sample
with a concentration above the 40,000-mIU/ml cutoff. Because
the eight cases with concentrations of 40,000 mIU/ml could
include primary measles cases, these cases were described as prob-
able RICs (pRIC) (see Fig. S1 in the supplemental material). The
GMCs of all of the serum samples from the 17 cRICs (130,205
mIU/ml) and the 8 pRICs (41,345 mIU/ml) were not significantly
different (P  0.1821) (see Fig. S2 and Table S1 in the supplemen-
tal material).
Effect of the timing of serum collection on the presence of
measles IgM and the rise in measles neutralizing antibody con-
centrations among the 57 RICs. The fold increases in the PRN
titers determined for 34 RICs ranged from 2- to 9,118-fold, with
intervals between serum collections ranging from 2 to 29 days (see
Table S2 in the supplemental material). Two of the RICs (cases 33
and 34) showed no change in titer with intervals of 7 and 18 days
between sample collections. There was no correlation between the
magnitude of the fold change in PRN titer and the length of the
interval between sample collections, nor was there a correlation
between the magnitude of the measles neutralizing antibody con-
centration and detection of IgM (data not shown).
Multiple serum samples were collected from two of the RICs
(cases 7 and 14; see Table S2 in the supplemental material) in-
cluded in the ROC analyses (Fig. 4). Case 7 was that of a 49-year-
old health care worker who was reported to have had no detectable
IgG despite the receipt of three doses of MMR vaccine. The first
serum sample, drawn 1 week after exposure to a person with a
confirmed case of measles, was positive for measles IgG, and the
concentration was 36 mIU/ml. Case 14 was that of a 25-year-old
student, born abroad, who was reported to have received one dose
of MMR vaccine (undocumented) at 12 months of age. The IgG
concentrations in these two RICs increased rapidly after rash on-
set and reached peak titers before 10 days after rash onset. Between
1 and 2 months after rash onset, the elevated concentrations had
fallen below 40,000 mIU/ml (Fig. 4).
Analysis of GMCs of noncases, RICs, cRICs, and pRICs strat-
ified by timing of serum collection. The GMCs of all of the serum
samples, regardless of the timing of collection from the noncases
(n  20), RICs (n  57), cRICs (n  17), and pRICs (n  8), were
1,385, 24,325, 130,205, and 41,345 mIU/ml, respectively (data not
shown). The serum samples from these four groups were stratified
into four intervals based on the timing of serum collection after
rash onset for analysis of the GMCs (Table 2). The three RIC
groups (RICs, cRICs, and pRICs) showed similar trends in the
FIG 3 Concentrations of measles neutralizing antibodies determined by PRN assays of serum specimens from RICs and noncases used in the ROC curve analysis.
Concentrations (mIU/ml) are shown as box-and-whisker (BW) plots. The whiskers represent the values within the 10th to the 90th percentiles, and the median
and 25th and 75th percentiles are depicted by the horizontal lines in the boxes. Individual data points are shown; outliers are shown as black circles, and extreme
outliers are shown as triangles (noncases) and squares (RICs). GMCs are shown above the BW plots. The P values shown are for the difference between the GMCs
of serum specimens from RICs in ROC1 and ROC2. Statistical significance, P  0.05. N is the number of samples in each BW plot.
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timing of the rise and fall of measles neutralizing antibody con-
centrations that were observed for two RICs with multiple serum
collections (Fig. 4). Because of some low concentrations in serum
samples collected 2 days after rash onset among the RICs and
pRICs, the GMC in the noncases was not significantly different
from that in the RICs (P  0.1773) or the pRICs (P  0.8258) for
the time interval of 0 to 2 days. After 3 days, the measles neutral-
izing antibody concentrations increased among all of the cases
identified as RICs, cRICs, and pRICs. All three of these RIC groups
demonstrated a trend of decreasing concentrations at 8 days after
rash onset.
DISCUSSION
Laboratory confirmation of all suspected cases of measles is a crit-
ical element of surveillance and control activities during out-
breaks, especially in a postelimination setting. In areas with a low
prevalence of measles, the likelihood of a false-positive IgM result
greatly increases regardless of the assay used. Forty-five percent of
the initial serum samples submitted from the noncases in this
study were positive by the CDC IgM capture assay, whereas 65%
of these serum samples had previously tested positive for measles
IgM by other commercial assays. Three noncases for which an
etiology of rash illness was determined were attributed to parvo-
virus B19, enterovirus, and chikungunya virus. In the context of a
febrile rash illness in a highly vaccinated population, a positive (or
negative) IgM result from an acute-phase serum sample is difficult
to interpret and a sample for RT-PCR may not be available. There-
fore, additional assays to confirm measles reinfections may prove
useful, particularly in elimination settings.
The evaluation of the RICs and noncases by ROC analysis con-
firmed that high concentrations of measles neutralizing antibod-
ies can accurately identify RICs among suspected cases of measles
that have high-avidity measles IgG. A measles neutralizing anti-
body concentration of 40,000 mIU/ml was selected as the mini-
mum concentration for confirmation of a RIC among suspected
measles cases. In this study, concentrations of 40,000 mIU/ml
confirmed 41 (83.7%) of 49 RICs with serum collected 3 days
after rash onset. Many of the RICs in this study had measles neu-
tralizing antibody concentrations of 40,000 mIU/ml as early as
the day of rash onset, which is not surprising, since exposure to
virus typically occurs 12 to 14 days prior to the appearance of a
rash. However, since a larger proportion of the serum samples that
reached the threshold antibody concentration were collected 3
days after rash onset, a second serum sample may need to be tested
to confirm a RIC. Collection of serum at day 3 or later is consistent
with the surveillance recommendation (28) to collect a second
blood sample if the first serum sample collected 3 days after rash
onset is IgM negative or the result is inconclusive.
While many RICs may be confirmed as measles cases by epide-
miologic association with another confirmed case, other situa-
tions may require laboratory confirmation. Detection of measles
FIG 4 Concentrations of measles neutralizing antibodies determined by PRN assays of serum specimens from two of the RIC patients from whom multiple
serum samples were collected. The graph shows concentrations of measles neutralizing antibodies and days of serum sample collection relative to rash onset.
TABLE 2 GMCs and 95% CIs of serum specimens from noncases, RICs, cRICs, and pRICS stratified according to timing of serum collection
Daysb
Noncasesa RICs cRICs pRICs
No. of
samples GMCc (95% CI)
No. of
samples GMC (95% CI)
No. of
samples GMC (95% CI)
No. of
samples GMC (95% CI)
0–2 12 1,322 (674–2,593) 36 5,214 (2,884–9,429) 5 105,714 (43,932–248,686) 3 1,904 (1,573–2,102)
3–4 4 2,859 (1,838–4,553) 16 52,819 (24,570–113,551) 4 136,888 (68,906–177,788) 3 157,012 (102,871–193,883)
5–7 9 1,838 (741–4,553) 21 102,163 (68,788–151,732) 2 197,124 (156,289–248,628) 3 200,993 (187,189–208,590)
8–42 13 951 (478–1,895) 15 57,485 (23,022–143,537) 11 130,350 (61,547–206,580) 2 55,924 (47,986–65,176)
a PRN assay-determined measles neutralizing antibody concentrations identified as outliers were excluded.
b Days are after rash onset.
c The GMCs were calculated for concentrations of measles neutralizing antibodies measured in mIU/ml.
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virus RNA by RT-PCR has become a widely available method for
case confirmation, but failure to promptly collect appropriate
specimens may reduce the utility of RT-PCR. Most of the fol-
low-up serum samples in this study were late acute-phase serum
samples rather than convalescent-phase samples, which are usu-
ally collected at least 2 weeks after the acute-phase serum sample
for evaluation of a 4-fold rise in antibody titer. Collection of a
standard convalescent-phase serum sample among suspected
RICs would not be advantageous, since a rise in titer may not be
observed because of the early and robust anamnestic response in
most RICs. Rapid increases in measles neutralizing antibody
concentrations in RICs were observed with intervals as short as
1 to 3 days between serum sample collections. However, a con-
centration of 40,000 IU/ml in a single serum sample with
high-avidity measles IgG from a suspected measles case is suf-
ficient to confirm a RIC.
Other investigators have noted the presence of high levels of
measles IgG in acute-phase serum samples from measles cases in
previously vaccinated individuals, although detection of IgM has
varied, depending on the timing of serum sample collection and
the measles IgM assay used (29–32). In the present study, 68% of
the RICs that had a follow-up serum sample (n  21) had a pos-
itive IgM result. Although many of the RICs in this study had early
acute-phase serum samples that were strongly positive in the mea-
sles IgG EIA, individuals with rash illnesses attributable to other
etiologic agents may also show strong reactivity in the measles IgG
EIA as a result of immunologic stimulation and production of
polyclonal IgG (33).
Measles reinfection has been described as modified measles.
This term was used as early as 1963 to describe cases of measles in
vaccinated individuals, as well as in patients given immunoglob-
ulin as postexposure prophylaxis who later showed a mild clinical
presentation (34). Although cases of modified measles have been
characterized as having a shorter or a less severe disease course
than a primary infection, some RICs exhibited symptoms that
meet the clinical case definition (11, 15, 21, 35–37). Although
clinical descriptions were not routinely collected, many of the
RICs included in the present study were described as having mild
symptoms and/or a nonclassic presentation of rash. There is evi-
dence to suggest that individuals with a reinfection are less likely to
transmit virus than a primary case of measles (18–20). However,
approximately 10% of the RICs in this study were identified as the
source of infection of another case. This may reflect a bias associ-
ated with RICs that are both recognized and referred to the CDC
that may be different in both clinical features and the potential for
transmission.
Symptomatic cases of measles in individuals who have been
vaccinated have been recognized since shortly after the measles
immunization program began (34, 38–40) and were described in
reports of school outbreaks in the 1980s (41, 42). It is likely that
many of the vaccine failures that occurred during outbreaks in the
1960s to the 1980s were mistakenly attributed to PVF because of
the prevailing view that detection of IgM defined a primary im-
mune response (30, 37, 43–46). Previously vaccinated individuals
who contract measles are described as having an SVF upon the
demonstration of high-avidity measles IgG. Although waning im-
munity (waning antibody) with time after MMR vaccination has
been described (47, 48), it may not be accurate to attribute all cases
of vaccine failure to waning immunity. The presence of high-avid-
ity measles IgG antibody signifies a prior response to measles but
does not provide assurance that the primary response following
vaccination reached a protective titer. Immunologic mechanisms
that influence both the extent of the initial response and the du-
ration of vaccine-induced antibodies may be influenced by indi-
vidual genetic differences, or other causes may contribute to in-
complete immunity (49–54). Although high coverage with two
doses of MMR vaccine has eliminated measles in the United
States, vaccination may fail to stimulate a protective level of anti-
body in some individuals, even after two doses of MMR vaccine
(16, 52, 55).
Eight of 74 RICs (including the cRICs) in this study were re-
corded as unvaccinated yet had high-avidity measles IgG. These
individuals may have received a vaccination early in life, or it is
possible that they had measles in childhood. Three of the RIC
patients were 52 years of age, and two of these were born over-
seas in a country where measles was endemic. There are reports of
individuals who have been reinfected despite natural measles in
childhood; however, documentation of measles disease is not usu-
ally available and prior vaccination is difficult to rule out (11, 13,
36, 38).
This study has several limitations. Eight (14%) of the RIC
patients had neutralizing antibody concentrations of 40,000
mIU/ml at 3 days after rash onset. The measles neutralizing
antibody concentrations of these individuals ranged from 402 to
29,367 mIU/ml, and the samples were collected on days 3 to 24
after rash onset. This suggests that a proportion of RICs may not
elicit a robust neutralizing antibody response regardless of the
interval from rash to serum sample collection. Therefore, a neu-
tralizing antibody concentration of 40,000 mIU/ml should not
be used to rule out measles in an individual with high-avidity
measles IgG that has clinically compatible symptoms.
Another limitation is that the RICs and noncases included in
the ROC analyses may have been misclassified. A gold standard
assay for measles reinfection does not exist. Instead, high-avidity
measles IgG and either a positive RT-PCR result or a 4-fold rise in
titer between paired serum samples (or both) were considered
valid methods to confirm a RIC. The criteria for a noncase re-
quired both the absence of a 4-fold rise in PRN titer and a corrob-
orating negative RT-PCR result. However, negative results by ei-
ther or both assays among suspected cases with high-avidity IgG
could result in misclassification of a RIC as a noncase. Indeed, a
negative result by RT-qPCR and a very high measles neutralizing
antibody level in the first serum sample eliminated the ability to
demonstrate a rise in titer and resulted in the inclusion of a RIC
among the noncases (case X). The other noncases had a low sus-
picion of measles and had been ruled out following extensive in-
vestigations. The presence of high-avidity measles IgG antibody in
serum from the noncases would exclude the possibility of a pri-
mary infection with measles.
Finally, the noncases in our study may have had lower levels of
measles neutralizing antibody concentrations than what is typical
in the general population. The measles neutralizing antibody con-
centrations calculated for the 20 noncases (excluding a misclassi-
fied RIC) ranged from 165 to 13,083 mIU/ml (GMC  1,790
mIU/ml), which is consistent with data from other studies, many
of which measured measles antibody titers shortly after vaccina-
tion or revaccination (56–59). In one of those studies, 304 school
age children who received a second dose of MMR vaccine, even
those who were seronegative after the first dose, had a GMC of
2,814 mIU/ml (range, 371 to 16,400 mIU/ml) at 1 month after
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receipt of the second dose (56). Also, 85% of the noncases had a
history of vaccination and included several individuals who had
received an MMR vaccine within the previous 6 months.
The PRN assay is only available in a few reference or research
laboratories, since the test requires specialized reagents and train-
ing. The need for PRN testing to confirm RICs would be limited to
those settings in which endemic measles has been eliminated.
Even in such settings, it is not anticipated that many suspected
cases of measles would require PRN testing, since measles reinfec-
tions occur infrequently and RT-PCR is widely available. If incon-
clusive IgM results are obtained, RT-PCR should be utilized to
confirm suspected cases of measles whenever possible. Under
some circumstances, highly suspicious cases of measles that have
negative RT-PCR results may require additional testing. While
measles neutralizing antibody concentrations below the threshold
level cannot be used to rule out a case, concentrations of 40,000
mIU/ml can confirm the case, albeit retrospectively. Since the
PRN assay takes 7 to 10 days to complete, case investigations
should not be delayed while specialized additional testing is under
way. However, in an elimination setting, this additional method
can aid in confirming RICs that cannot be resolved by standard
techniques and have no epidemiologic link to a laboratory-con-
firmed measles case.
High vaccination coverage has successfully prevented measles
from reestablishing endemic circulation in the United States de-
spite continuous importation of the virus (60). As immunization
programs worldwide are accelerating efforts to eliminate measles,
an additional serologic method to classify challenging cases of
measles may prove valuable. Further study is needed to determine
if a more convenient assay format, such as EIA or microbead, can
be developed or modified to generate results that correlate with
neutralizing antibody concentrations in the ranges described in
this study. Measles reinfections are likely to become more com-
mon when measles is introduced into highly vaccinated popula-
tions; therefore, additional data should be collected to evaluate the
settings in which these cases are most likely to occur and the po-
tential for further transmission from such cases.
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